Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241511887 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Katiane Tostes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Barretos Cancer Hospital (Brazil), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
Abstract (Originalsprache)
Lung cancer has the highest mortality rate among all cancer types, resulting in over 1.8 million deaths annually. Immunotherapy utilizing immune checkpoint inhibitors (ICIs) has revolutionized the treatment of non-small cell lung cancer (NSCLC). ICIs, predominantly monoclonal antibodies, modulate co-stimulatory and co-inhibitory signals crucial for maintaining immune tolerance. Despite significant therapeutic advancements in NSCLC, patients still face challenges such as disease progression, recurrence, and high mortality rates. Therefore, there is a need for predictive biomarkers that can guide lung cancer treatment strategies. Currently, programmed death-ligand 1 (PD-L1) expression is the only established biomarker for predicting ICI response. However, its accuracy and robustness are not consistently reliable. This review provides an overview of potential biomarkers currently under development or in the validation stage that hold promise in improving the classification of responders and non-responders to ICI therapy in the near future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil.
- Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, 4710-057 Braga, Portugal.
- ICVS/3B's-PT Government Associate Laboratory, 4806-909 Guimarães, Portugal.
- Barretos School of Health Sciences, Dr. Paulo Prata-FACISB, Barretos 14785-002, São Paulo, Brazil.
ORCID-Profile: Katiane Tostes, Aléxia Polo Siqueira, Rui Manuel Reis, Leticia Ferro Leal, Lidia Maria Rebolho Batista Arantes
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
- Barretos Cancer Hospital (Brazil)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Productivity (Brazil)
Zitieren
APA
Tostes, K., Siqueira, A. P., Reis, R. M., Leal, L. F., & Arantes, L. M. R. B. (2023). Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241511887
Vancouver
Tostes K, Siqueira AP, Reis RM, Leal LF, Arantes LMRB. Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241511887
BibTeX
@article{Tostes2023,
author = {Tostes, Katiane and Siqueira, Aléxia Polo and Reis, Rui Manuel and Leal, Leticia Ferro and Arantes, Lidia Maria Rebolho Batista},
title = {Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241511887}
}
EUVIMED